Sanofi SA (SNY)
49.15
-0.21
(-0.43%)
USD |
NASDAQ |
Apr 26, 16:00
49.15
0.00 (0.00%)
After-Hours: 20:00
Sanofi Research and Development Expense (Quarterly): 2.016B for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.016B |
| September 30, 2023 | 1.811B |
| June 30, 2023 | 1.777B |
| March 31, 2023 | 1.679B |
| December 31, 2022 | 1.864B |
| September 30, 2022 | 1.749B |
| June 30, 2022 | 1.766B |
| March 31, 2022 | 1.671B |
| December 31, 2021 | 1.813B |
| September 30, 2021 | 1.703B |
| June 30, 2021 | 1.684B |
| March 31, 2021 | 1.526B |
| June 30, 2020 | 1.489B |
| March 31, 2020 | 1.479B |
| December 31, 2019 | 1.869B |
| September 30, 2019 | 1.512B |
| June 30, 2019 | 1.783B |
| March 31, 2019 | 1.573B |
| December 31, 2018 | 1.915B |
| September 30, 2018 | 1.699B |
| June 30, 2018 | 1.761B |
| March 31, 2018 | 1.572B |
| December 31, 2017 | 1.724B |
| September 30, 2017 | 1.577B |
| June 30, 2017 | 1.494B |
| Date | Value |
|---|---|
| March 31, 2017 | 1.394B |
| December 31, 2016 | 1.550B |
| September 30, 2016 | 1.363B |
| June 30, 2016 | 1.445B |
| March 31, 2016 | 1.362B |
| December 31, 2015 | 1.355B |
| September 30, 2015 | 1.506B |
| June 30, 2015 | 1.377B |
| March 31, 2015 | 1.308B |
| December 31, 2014 | 1.491B |
| September 30, 2014 | 1.519B |
| June 30, 2014 | 1.629B |
| March 31, 2014 | 1.560B |
| December 31, 2013 | 1.472B |
| September 30, 2013 | 1.567B |
| June 30, 2013 | 1.548B |
| March 31, 2013 | 1.527B |
| December 31, 2012 | 1.756B |
| September 30, 2012 | 1.430B |
| June 30, 2012 | 1.586B |
| March 31, 2012 | 1.537B |
| December 31, 2011 | 1.711B |
| September 30, 2011 | 1.726B |
| June 30, 2011 | 1.725B |
| March 31, 2011 | 1.505B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.479B
Minimum
Mar 2020
2.016B
Maximum
Dec 2023
1.717B
Average
1.749B
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| AstraZeneca PLC | 3.073B |
| GSK PLC | 2.542B |
| Novo Nordisk A/S | 1.510B |
| Regeneron Pharmaceuticals Inc | 1.177B |
| Inhibrx Inc | 82.09M |